THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

Amgen recently received an expanded FDA approval for Repatha®, broadening its use for adults at risk of major cardiovascular events. During the same quarter, the company reported significant earnings ...